US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Franklin Genomic Advancements ETF

41.85

-0.5680-1.34%

Volume:244

Turnover:10.16K

Market Cap:29.30M

PE:- -

High:41.85

Open:42.42

Low:41.85

Close:42.42

52wk High:45.58

52wk Low:31.44

Shares:700.00K

Float Shares:700.00K

Volume Ratio:0.04

T/O Rate:0.03%

Dividend:0.14

Dividend Rate:0.34%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 6,444 Shares for $193,320

Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion

Guardant Health Wins EU CE Mark for Guardant360 CDx as Camizestrant Companion Diagnostic in ER-Positive Breast Cancer

Guardant Health Announces Approval in Europe of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Er-Positive Breast Cancer

THOMSON REUTERS

Guardant Health to Report Q3 2026 Financial Results After Market Close, Host Conference Call

How New Signatera Trial Data Will Impact Natera (NTRA) Investors

Simply Wall St.

All Invest Securities Reaffirms Buy Rating on ABL Texcell Diagnostics as Texcell Integration Boosts Growth Outlook

Guardant Health is Maintained at Overweight by Barclays

Natera Study of Signatera to Identify Skin Cancer Earlier Begins Enrollment

MT Newswires Live

Natera Enrolls First Patients in Signatera-Guided Melanoma Trial Evaluating Early Immunotherapy Escalation

Ligand Pharmaceuticals CLO, Secretary Andrew Reardon Disposes of USD 1.5 Million in Common Shares

Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know

Natera Inc Stock (NTRA) Moved Down by 5.30% on Oct 6: A Full Analysis

Natera announces new data shared at ASTRO 2026 on Signatera

Natera Presents New Signatera ctDNA Studies at Astro, Highlighting Radiation Oncology Use Cases

Forbion raises $2.6bn in a boost for Europe's biotech sector

Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 26,792 Common Shares Worth $770,481

Guardant Health reports COSMOS study published in Cancer Research Communications

Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences

Natera, Alliance Foundation Trials Launch Phase III Navigate Breast Cancer Study Using Signatera MRD-Guided Cdk4/6 Therapy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/HELX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"HELX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","market":"US","secType":"STK","nameCN":"Franklin Genomic Advancements ETF","latestPrice":41.8522,"timestamp":1791489600000,"preClose":42.4202,"halted":0,"volume":244,"delay":0,"changeRate":-0.013389847289734556,"floatShares":700000,"shares":700000,"eps":0,"marketStatus":"Pre-Mkt","change":-0.568,"latestTime":"10-09 05:31:47 EDT","open":42.4202,"high":41.8522,"low":41.8522,"amount":10157,"amplitude":0,"askPrice":66.54,"askSize":100,"bidPrice":16.83,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791552600000},"marketStatusCode":1,"adr":0,"exchange":"CBOE","adjPreClose":41.8522,"sharesOutstanding":650000,"nav":42.394,"aum":29675530.04,"dividendRate":0.003445,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":42.4202,"preClose":41.8522,"latestTime":"16:10 EDT","volume":7,"amount":292.9654,"timestamp":1791490204748,"change":0.568,"changeRate":0.013572,"amplitude":0},"volumeRatio":0.03608506551963128,"impliedVol":0.1194,"impliedVolPercentile":0.42},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HELX\",,,,,undefined,":{"symbol":"HELX","floatShares":700000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.03608506551963128,"shares":700000,"dividePrice":0.1442,"high":41.8522,"amplitude":0,"preClose":42.4202,"low":41.8522,"week52Low":31.44,"pbRate":"--","week52High":45.58,"institutionHeld":0,"latestPrice":41.8522,"eps":0,"divideRate":0.003445,"volume":244,"delay":0,"ttmEps":0,"open":42.4202,"prevYearClose":36.3062,"prevWeekClose":43.79,"prevMonthClose":44.5641,"prevQuarterClose":44.5641,"fiveDayClose":43.53,"twentyDayClose":41.0314,"sixtyDayClose":39.7145},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HELX\",params:#limit:5,,,undefined,":[{"date":"2025-12-30","symbol":"HELX","amount":0.14334,"announcedDate":"2025-12-29","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-30","defaultRemindTime":1767105000000,"name":"Franklin Genomic Advancements ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-01-08","payableDate":"2025-12-30","currency":"USD","dateTimestamp":1767070800000,"payDate":"2026-01-08"},{"market":"US","date":"2021-12-30","symbol":"HELX","amount":0.003935,"defaultRemindTime":1640874600000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2022-01-07","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000},{"market":"US","date":"2021-12-13","symbol":"HELX","amount":0.114148,"defaultRemindTime":1639405800000,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2021-12-21","payableDate":"2021-12-14","currency":"USD","type":"dividend","dateTimestamp":1639371600000},{"market":"US","date":"2020-12-14","symbol":"HELX","amount":0.005005,"name":"FRANKLIN GENOMIC ADVANCEMENTS ETF","recordDate":"2020-12-23","payableDate":"2020-12-15","currency":"USD","type":"dividend","dateTimestamp":1607922000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HELX\",market:\"US\",,,undefined,":[{"executeDate":"2020-12-14","recordDate":"2020-12-15","paymentDate":"2020-12-23","value":0.005005,"currency":"USD"},{"executeDate":"2021-12-13","recordDate":"2021-12-14","paymentDate":"2021-12-21","value":0.114148,"currency":"USD"},{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-07","value":0.003935,"currency":"USD"},{"executeDate":"2025-12-30","recordDate":"2025-12-30","paymentDate":"2026-01-08","value":0.14334,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HELX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HELX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2674885505","title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 6,444 Shares for $193,320","url":"https://stock-news.laohu8.com/highlight/detail?id=2674885505","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674885505?lang=en_us&edition=fundamental","pubTime":"2026-10-09 06:53","pubTimestamp":1791499999,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky sells 6,444 shares for $193,320Adaptive Biotechnologies Chief Commercial Officer, MRD Susan Bobulsky sold 6,444 common shares on Oct. 6","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL3KxJkn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief Commercial Officer Susan Bobulsky Sells 6,444 Shares for $193,320","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000684","title":"Guardant announces Europe approval of Guardnat360 CDx as Etcamaha companion","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000684","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000684?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:15","pubTimestamp":1791490537,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced that Guardant360 CDx has received CE-marking under Europe’s in Vitro Diagnostic Medical Devices Regulation as a comp...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-announces-europe-approval-of-guardnat360-cdx-as-etcamaha-companion-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-announces-europe-approval-of-guardnat360-cdx-as-etcamaha-companion-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","HELX","LU0889565916.HKD","PTH","LU0320765992.SGD","BK4196","LFSC","EKG","GH","LU0109394709.USD","FFOX","GNOM","BK4535","GDOC","BK4551","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674000800","title":"Guardant Health Wins EU CE Mark for Guardant360 CDx as Camizestrant Companion Diagnostic in ER-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674000800","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674000800?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:12","pubTimestamp":1791490344,"startTime":"0","endTime":"0","summary":"Guardant Health wins EU CE mark for Guardant360 CDx as camizestrant companion diagnostic in ER-positive breast cancerGuardant Health secured EU CE-marking for Guardant360 CDx as a companion diagnostic","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDL7WpmQr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765992.SGD","LU0889565916.HKD","LU0109394709.USD","PTH","GDOC","GH","HELX","FFOX","GNMX","BK4588","BK4196","BK4551","GNOM","BK4585","LFSC","EKG","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674802000","title":"Guardant Health Announces Approval in Europe of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Er-Positive Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2674802000","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674802000?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:12","pubTimestamp":1791490320,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nTUA8LV3XK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0784385840.USD","LU0345777659.USD","LU2023251221.USD","LU0997586515.USD","LU2237443622.USD","LU0661504455.SGD","LU0345777147.USD","EKG","HELX","AZN.UK","LU0029864427.USD","LU0960981461.USD","LU0011850046.USD","LU0784383803.USD","LU0757432116.USD","FFOX","GDOC","IE00B3T34201.USD","LU1153585028.USD","LU1261432733.SGD","LU2125909247.SGD","GH","GNMX","LU1153584641.USD","LU1323610961.USD","LU0949170426.SGD","LU1496350171.SGD","LU0827474353.SGD","LU1863844749.USD","IE00BJT1NW94.SGD","LU0949170772.SGD","LU0823399737.USD","LU1481599808.USD","LU1267930813.SGD","LFSC","LU1923622614.USD","LU2539964713.USD","LU1015430645.USD","LU1057294990.SGD","LU1989772923.USD","03165","LU0972486137.USD","LU0882574055.USD","LU0058720904.USD","LU2293690249.USD","PTH","GNOM","LU0823416689.USD","LU0211326755.USD","LU0526926950.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674007701","title":"Guardant Health to Report Q3 2026 Financial Results After Market Close, Host Conference Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2674007701","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674007701?lang=en_us&edition=fundamental","pubTime":"2026-10-09 04:05","pubTimestamp":1791489926,"startTime":"0","endTime":"0","summary":"Guardant Health to report Q3 2026 financial results after market close, host conference callGuardant Health schedules third-quarter 2026 results release for Nov. 5, 2026, following the market close.Ma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261008:nNDLWjfQL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","HELX","LU0320765992.SGD","BK4535","FFOX","GNOM","BK4585","LU0889565916.HKD","BK4588","GH","PTH","LFSC","GDOC","EKG","GNMX","BK4551","BK4196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674300767","title":"How New Signatera Trial Data Will Impact Natera (NTRA) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2674300767","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674300767?lang=en_us&edition=fundamental","pubTime":"2026-10-09 03:29","pubTimestamp":1791487753,"startTime":"0","endTime":"0","summary":"Natera reported several new Signatera milestones, including first patient enrollment in an NYU Langone melanoma trial and fresh ASTRO 2026 data across rectal, anal, cervical, and vulvovaginal cancers.\nThe combination of melanoma trial enrollment and multi tumor Signatera evidence highlights how deeply molecular residual disease testing is being built into real-world treatment decisions.\nWe will now look at how Natera's expanding Signatera trial footprint could influence how investors view...","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/how-new-signatera-trial-data-will-impact-natera-ntra-investo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/how-new-signatera-trial-data-will-impact-natera-ntra-investo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0345770308.USD","LU0012050646.USD","ISBC","HELX","BK4139","LU1064131342.USD","LU2065171402.SGD","LU2065170008.USD","LU2324357040.USD","GNOM","LU0106261612.USD","LU2065171311.SGD","LU0053671581.USD","NTRA","LU2065169927.USD","LU0963586101.USD","BK4211","LU2065731478.USD","LU1988902786.USD","LU2264538146.SGD","LU0345770993.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673771071","title":"All Invest Securities Reaffirms Buy Rating on ABL Texcell Diagnostics as Texcell Integration Boosts Growth Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2673771071","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673771071?lang=en_us&edition=fundamental","pubTime":"2026-10-08 19:36","pubTimestamp":1791459400,"startTime":"0","endTime":"0","summary":"ABL Diagnostics SA ( ($FR:ABLD) ) has issued an update. ABL Texcell Diagnostics, listed on Euronext Paris, develops molecular diagnostics, healthca...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/all-invest-securities-reaffirms-buy-rating-on-abl-texcell-diagnostics-as-texcell-integration-boosts-growth-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/all-invest-securities-reaffirms-buy-rating-on-abl-texcell-diagnostics-as-texcell-integration-boosts-growth-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HTEC","BMED","HELX","ABLD","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673162670","title":"Guardant Health is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2673162670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673162670?lang=en_us&edition=fundamental","pubTime":"2026-10-07 22:43","pubTimestamp":1791384180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FFOX","GNOM","BK4588","GH","LU0109394709.USD","LU0320765992.SGD","BK4585","GDOC","PTH","BK4551","GNMX","EKG","BK4196","HELX","LU0889565916.HKD","LFSC","BK4535"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673301867","title":"Natera Study of Signatera to Identify Skin Cancer Earlier Begins Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=2673301867","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673301867?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:25","pubTimestamp":1791375915,"startTime":"0","endTime":"0","summary":"Natera  said Wednesday that patient enrollment has begun for a trial using its Signatera test to identify patients who may need earlier intervention by detecting persistent molecular residual disease before radiographic progression.The company said the study will use Signatera to guide treatment escalation for patients with advanced or metastatic melanoma, which is an aggressive type of skin cancer. It said the current standard of care is a combination immunotherapy until clinical progression.The company said the primary endpoint is progression-free survival.The study is sponsored by NYU Langone Health.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2264538146.SGD","LU0963586101.USD","LU1988902786.USD","GNOM","LU0106261612.USD","LU2324357040.USD","LU2065731478.USD","BK4139","LU0012050646.USD","LU2065170008.USD","LU0053671581.USD","LU0345770308.USD","LU1064131342.USD","LU2065169927.USD","LU2065171402.SGD","NTRA","LU0345770993.USD","HELX","LU2065171311.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673909044","title":"Natera Enrolls First Patients in Signatera-Guided Melanoma Trial Evaluating Early Immunotherapy Escalation","url":"https://stock-news.laohu8.com/highlight/detail?id=2673909044","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673909044?lang=en_us&edition=fundamental","pubTime":"2026-10-07 20:01","pubTimestamp":1791374490,"startTime":"0","endTime":"0","summary":"Natera enrolls first patients in Signatera-guided melanoma trial evaluating early immunotherapy escalationNatera reported first patient enrollment in a randomized melanoma trial using its Signatera te","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL5QNCJW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HELX","LU2065171311.SGD","LU2065170008.USD","BK4139","LU1064131342.USD","NTRA","LU0053671581.USD","LU0963586101.USD","GNOM","LU0106261612.USD","LU0345770993.USD","LU2065731478.USD","LU2324357040.USD","LU0012050646.USD","LU0345770308.USD","LU2065169927.USD","LU2065171402.SGD","LU1988902786.USD","LU2264538146.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673065809","title":"Ligand Pharmaceuticals CLO, Secretary Andrew Reardon Disposes of USD 1.5 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2673065809","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673065809?lang=en_us&edition=fundamental","pubTime":"2026-10-07 04:36","pubTimestamp":1791318977,"startTime":"0","endTime":"0","summary":"Ligand Pharmaceuticals CLO, Secretary Andrew Reardon disposes of USD 1.5 million in common sharesLigand Pharmaceuticals CLO and Secretary Andrew Reardon cut his common stock stake to 31,854 shares on ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL641K88:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Ligand Pharmaceuticals CLO, Secretary Andrew Reardon Disposes of USD 1.5 Million in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0566484027.USD","IE0009354923.USD","LU1559883803.SGD","HELX","BK4139","BK4007","LGND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673068758","title":"Guardant Health Inc Stock (GH) Moved Down by 8.27% on Oct 6: What Investors Need To Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2673068758","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673068758?lang=en_us&edition=fundamental","pubTime":"2026-10-07 03:15","pubTimestamp":1791314128,"startTime":"0","endTime":"0","summary":"• Guardant Health shares dropped due to profit-taking after a multi-month rally.\n• Ongoing unprofitability and high valuation multiples triggered intense selling pressure.\n• The company reported $982.02M in annual revenue and a net profit of $-416.28M.","market":"nz","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262202416-market-movers-gh-20261006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","LU0320765992.SGD","BK4585","EKG","FFOX","GDOC","BK4196","LU0109394709.USD","GNOM","GNMX","LU0889565916.HKD","PTH","HELX","BK4588","GH","BK4535","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673805012","title":"Natera Inc Stock (NTRA) Moved Down by 5.30% on Oct 6: A Full Analysis","url":"https://stock-news.laohu8.com/highlight/detail?id=2673805012","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673805012?lang=en_us&edition=fundamental","pubTime":"2026-10-07 01:15","pubTimestamp":1791306925,"startTime":"0","endTime":"0","summary":"• Natera shares pulled back due to broad profit-taking after recent peak levels.\n• Elevated valuations and insider share sales fueled recent short-term selling pressure.\n• Core fundamentals remain strong with robust volume growth across precision medicine portfolios.","market":"other","thumbnail":"https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cms_uploads/img/20230814/292a73ea96beb98e5f665e124a82e00c.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/market-movers/262202265-market-movers-ntra-20261006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1988902786.USD","LU2065731478.USD","LU2065171402.SGD","NTRA","LU0345770993.USD","LU0963586101.USD","LU2264538146.SGD","LU0053671581.USD","LU2065170008.USD","LU2065169927.USD","LU0345770308.USD","LU2324357040.USD","LU2065171311.SGD","LU0106261612.USD","LU1064131342.USD","GNOM","BK4139","LU0012050646.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056732","title":"Natera announces new data shared at ASTRO 2026 on Signatera","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056732","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056732?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:11","pubTimestamp":1791288669,"startTime":"0","endTime":"0","summary":"Natera (NTRA) announced new data recently shared at the American Society for Radiation Oncology, ASTRO, 2026 Annual Meeting. The presentations mark...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/natera-announces-new-data-shared-at-astro-2026-on-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/natera-announces-new-data-shared-at-astro-2026-on-signatera-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171311.SGD","LU0012050646.USD","LU0963586101.USD","NTRA","LU2065170008.USD","LU2065169927.USD","LU1988902786.USD","GNOM","LU1064131342.USD","LU2065731478.USD","LU0053671581.USD","HELX","LU0345770308.USD","LU2264538146.SGD","LU2065171402.SGD","LU2324357040.USD","LU0106261612.USD","LU0345770993.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673056597","title":"Natera Presents New Signatera ctDNA Studies at Astro, Highlighting Radiation Oncology Use Cases","url":"https://stock-news.laohu8.com/highlight/detail?id=2673056597","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673056597?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:03","pubTimestamp":1791288234,"startTime":"0","endTime":"0","summary":"Natera presents new Signatera ctDNA studies at ASTRO, highlighting radiation oncology use casesNatera reported new Signatera clinical data already presented at the ASTRO 2026 annual meeting, its first","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDLb3spFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065169927.USD","LU0053671581.USD","HELX","NTRA","LU2065731478.USD","LU0012050646.USD","LU2065170008.USD","LU0106261612.USD","BK4139","LU0345770308.USD","LU1064131342.USD","LU2065171311.SGD","LU0963586101.USD","LU2324357040.USD","GNOM","LU1988902786.USD","LU0345770993.USD","LU2264538146.SGD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187292056","title":"Forbion raises $2.6bn in a boost for Europe's biotech sector","url":"https://stock-news.laohu8.com/highlight/detail?id=1187292056","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187292056?lang=en_us&edition=fundamental","pubTime":"2026-10-06 20:00","pubTimestamp":1791288033,"startTime":"0","endTime":"0","summary":"This Dutch firm has completed a large fundraising round, even as European drugmakers and investors keep warning that the region's competitiveness is slipping.European pharmaceutical executives have...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDNA","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673806850","title":"Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 26,792 Common Shares Worth $770,481","url":"https://stock-news.laohu8.com/highlight/detail?id=2673806850","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673806850?lang=en_us&edition=fundamental","pubTime":"2026-10-06 08:13","pubTimestamp":1791245613,"startTime":"0","endTime":"0","summary":"Adaptive Biotechnologies Chief People Officer Francis Lo disposes of 26,792 common shares worth $770,481Adaptive Biotechnologies Chief People Officer Francis Lo sold 26,792 shares on Oct. 1, 2026 at U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261006:nNDL73r6bl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Adaptive Biotechnologies Chief People Officer Francis Lo Disposes of 26,792 Common Shares Worth $770,481","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ADPT","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673085570","title":"Guardant Health reports COSMOS study published in Cancer Research Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085570?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:30","pubTimestamp":1791214209,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced Cancer Research Communications, a journal of the American Association for Cancer Research, has published results fro...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-reports-cosmos-study-published-in-cancer-research-communications-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","EKG","HELX","GNMX","BK4585","FFOX","BK4588","LU0320765992.SGD","LU0889565916.HKD","BK4196","GNOM","PTH","LFSC","BK4551","BK4535","GDOC","GH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673085807","title":"Guardant Health Cosmos-MEL01 Study Shows Guardant Reveal Detects 81% of Distant Melanoma Recurrences","url":"https://stock-news.laohu8.com/highlight/detail?id=2673085807","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673085807?lang=en_us&edition=fundamental","pubTime":"2026-10-05 23:27","pubTimestamp":1791214069,"startTime":"0","endTime":"0","summary":"Guardant Health COSMOS-MEL01 study shows Guardant Reveal detects 81% of distant melanoma recurrencesGuardant Health disclosed published results from a prospective, multicenter COSMOS study evaluating ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL5cqdWm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LFSC","GNMX","BK4535","GH","BK4196","GDOC","BK4585","EKG","FFOX","GNOM","PTH","BK4588","BK4551","LU0320765992.SGD","LU0109394709.USD","HELX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673024077","title":"Natera, Alliance Foundation Trials Launch Phase III Navigate Breast Cancer Study Using Signatera MRD-Guided Cdk4/6 Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2673024077","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673024077?lang=en_us&edition=fundamental","pubTime":"2026-10-05 20:08","pubTimestamp":1791202097,"startTime":"0","endTime":"0","summary":"Natera, Alliance Foundation Trials launch Phase III NAVIGATE breast cancer study using Signatera MRD-guided CDK4/6 therapyNatera joined Alliance Foundation Trials, Genentech to launch AFT-70 NAVIGATE,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL69ccGs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRA","BK4139","LU2065169927.USD","LU0345770308.USD","LU2065171311.SGD","LU2324357040.USD","GNOM","LU2065731478.USD","LU1064131342.USD","HELX","LU0106261612.USD","LU0012050646.USD","LU2264538146.SGD","LU2065170008.USD","LU0345770993.USD","LU0963586101.USD","LU1988902786.USD","LU0053671581.USD","LU2065171402.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}